Archived COVID-19 Resources for Clinicians
Please review ASH's disclaimer regarding the use of the following information. The FAQs available on this page are not being regularly updated. The information contained herein is only accurate as of the date listed, which represents the last time the information was reviewed by experts. For the latest information on COVID-19 treatments, please review ASH’s COVID resources; previously available resources can be accessed via the archives.
Academic Centers, Hospitals, and Community Practices
- Brigham and Women's Hospital (COVID-19 Critical Care Clinical Guidelines)
- Seattle Cancer Care Alliance (patient screening and testing tools, PPE donning and doffing videos, telehealth FAQs)
- University of Washington (Screening and testing algorithms, policies and procedures)
Archived Frequently Asked Clinical Questions
Treatments and Prevention
- General Principles of COVID-19 Vaccines for Immunocompromised Patients (Version 6.1; last April 14, 2022)
- COVID-19 Therapies: Monoclonal Antibodies, Convalescent Plasma and Medications (Version 9.2; last updated April 7, 2022)
- Prevention of COVID-19 in Immunocompromised Patients With Hematologic Conditions (Version 2; last updated April 6, 2023)
Malignant Topics
- COVID-19 and Aggressive Non-Hodgkin Lymphoma (Version 6.0; last updated April 1, 2022)
- COVID-19 and Acute Lymphoblastic Leukemia - Adult (Version 2.1; last updated January 22, 2021)
- COVID-19 and Acute Lymphoblastic Leukemia - Pediatric (Version 3.0; last updated January 29, 2021)
- COVID-19 and Acute Myeloid Leukemia (Version 1.5; last reviewed January 19, 2022)
- COVID-19 and Chronic Lymphocytic Leukemia (Version 4.1; last updated February 2, 2021)
- COVID-19 and Chronic Myeloid Leukemia (Version 3.0; last updated September 28, 2021)
- COVID-19 and Hematopoietic Cell Transplantation (Version 2.0; last updated April 1, 2022)
- COVID-19 and Hodgkin Lymphoma (Version 6.0; last updated April 1, 2022)
- COVID-19 and Indolent Lymphomas (Version 6.0; last updated April 1, 2022)
- COVID-19 and Myelodysplastic Syndromes (Version 4.2; last updated May 17, 2021)
- COVID-19 and Myeloproliferative Neoplasms (Version 6.0; last updated September 3, 2021)
- COVID-19 and Multiple Myeloma (Version 2.1; last updated January 22, 2021)
Non-malignant Topics
- COVID-19 and Aplastic Anemia (Version 3.0; last updated May 6, 2021)
- COVID-19 and Immune Thrombocytopenic Purpura (Version 6.1; last updated April 21, 2021)
- COVID-19 and Sickle Cell Disease (Version 6.1; last updated May 28, 2021)
- COVID-19 and Thalassemia (Version 2.1; last updated January 19, 2022)
- COVID-19 and Thrombotic Thrombocytopenic Purpura (Version 3.3; last updated April 4, 2022)
- COVID-19 and VTE/Anticoagulation (Version 14.0; last updated February 2, 2022)
Clinical Laboratory Topics
- COVID-19 and aPL Antibodies (Version 1.1; last updated February 2, 2022)
- COVID-19 and D-dimer (Version 1.0; last updated April 20, 2020)
- COVID-19 and Viscoelastic Hemostasis Assays (Version 2.0; last updated February 25, 2021)
Clinical FAQ Resources from Other Societies
COVID-19 Treatments
Guidance About COVID-19 Treatment
- Assessment of Evidence for COVID-19 related treatments
- Tables of COVID-19 drug-drug interactions
- NIH COVID treatment guidance
- CDC Clinician On-Call Center
24-hour access to CDC clinicians to answer COVID-19 questions.
Clinical Trials and Studies
COVID-19 Registries for Hematologic Conditions
- ASH RC COVID-19 Registry for Hematology
The ASH Research Collaborative’s (ASH RC) Data Hub is capturing data on people who test positive for COVID-19 and have been or are currently being treated for a hematologic condition. As data are received, near real-time observational data summaries are reported for clinicians on the front line of the COVID-19 pandemic. Clinicians and other health care providers worldwide are invited to enter de-identified data on all confirmed COVID-19 cases for hematology patients, regardless of recovery or active treatment status. Online data entry takes approximately 5 minutes to complete. - Secure-SCD Registry (Medical College of Wisconsin)
This registry is designed to capture pediatric and adult COVID-19 cases that are occurring across the world in patients living with sickle cell disease. - CCC19 (COVID-19 and Cancer Consortium)
A consortium of over 100 cancer centers and other organizations who have come together to collect data about cancer patients who have been infected with COVID-19.
Restarting Routine Clinical Practice
Additional Resources
American Society of Hematology
- ASH Policy Resources
- ASH Summary of American Rescue Plan Act of 2021
- ASH Summary of the Coronavirus Aid, Relief and Economic Security (CARES) Act
- Latest COVID-19 Resources from ASH Publications
- Blood: Latest COVID-19 Articles
- Blood Advances: Latest COVID-19 Articles
- ASH Clinical News: COVID-19 News
- The Hematologist: COVID-19 Articles and Podcasts
Archived Webinars
- Webinar: Town Hall on NIH-organized Trials of Antithrombotic Agents in Patients with COVID-19: Hear the Latest and Become Involved in ACTIV-4
- Webinar: ASH Guidelines on Use of Anticoagulation in Patients with COVID-19
- Webinar: Sickle Cell Disease and COVID-19 Management in the Emergency Department
HHS (Department of Health and Human Services)
COVID-19: General Resources
Institute for Health Metrics and Evaluation
Johns Hopkins COVID tracker
AMA (American Medical Association)
CDC (Centers for Disease Control and Prevention)
WHO (World Health Organization)
Subspecialty Societies
AABB (American Association of Blood Banks)
ACP (American College of Physicians)
ASCO (American Society of Clinical Oncology)
ASTCT (American Society for Transplantation and Cellular Therapy)
EBMT (European Society for Blood Marrow Transplantation)
EHA (European Hematology Association)
IDSA (Infectious Diseases Society of America)
ISTH (International Society of Thrombosis and Hemostasis)
NCCN (National Comprehensive Cancer Network)
Journals
New England Journal of Medicine
JAMA (Journal of the American Medical Association)
The Lancet
Journal of Thrombosis and Haemostasis
UpToDate
British Journal of Haematology
Additional Resources
- Coronavirus Tech Handbook (manual for front-line providers)
Resources for Researchers
American Society of Hematology
- ASH COVID-19 Research Agenda for Hematology
- Summary of NIH Guidance on Grants, Operations During COVID-19 Response
FDA (Food and Drug Administration)
- FDA statistical considerations for clinical trials during COVID
- FDA Guidance on Clinical Trials
- FDA issues guidance on emergency INDs for convalescent plasma for COVID-19
NIH (National Institutes of Health)
- COVID-19 Seroprevalence Studies Hub
CDC and NIH have developed the COVID-19 Seroprevalence Studies Hub to provide an interactive dashboard to compare COVID19 serology studies across the country. - Summary of NIH ACTIV trials: Accelerating COVID-19 therapeutic interventions and vaccines
- NOSI from NIAID for Limited Clinical Trials to Evaluate Therapeutic and Vaccine Candidates Against SARS-CoV02 – expires 9/1/2021
- COVID-19: Information for NIH Applicants and Recipients of NIH Funding
Other Resources
- LitCovid: a curated literature hub by NLM
This hub tracks up-to-date scientific information about COVID-19. Articles are updated daily and are categorized by different research topics and geographic locations.
- Blood and Bone Seminar
Dr. Kellie Machlus from Harvard Medical School and Brigham and Women’s Hospital has organized this seminar series to continue scientific education during this time of travel restrictions and meeting cancellations. - Connecting the Scientific Community Seminar Series
Drs. Kornelia Polyak and David Weinstock from Dana-Farber/Harvard Cancer Center have organized this seminar series (12:00 pm Eastern every Tuesday and Thursday) to facilitate scientific exchanges during the COVID-19 restrictions.
Resources for Trainees
Frequently Asked Questions
- COVID-19 and Trainees: General Information (Version 1.1; last updated October 6, 2020)
- COVID-19 and Fellows (Version 1.1; last updated October 6, 2020)
- COVID-19 and Postdoctorate Students (Version 1.1; last updated October 6, 2020)
- COVID-19 and Residents (Version 1.1; last updated October 6, 2020)
Help ASH Build an Inclusive Hematology Community!
ASH is committed to building and nurturing a global hematology community and workforce inclusive of diverse perspectives, talents, and experiences as it works toward one collective goal: helping hematologists conquer blood diseases worldwide.
How Can You Help?
Visit your My Account page, make needed updates to your demographic details, and select your preferred level of ASH access to your information; aggregated or individually identifiable, or choose not to provide or share your information. By sharing information about who you are, you will help ASH have a better appreciation of the diverse needs and talents present in the field, and help to build a more inclusive, collaborative hematology community. It will take only a few moments to complete!
Update Access to Demographic Information Learn About Our Mission